D. E. Shaw & Co. Inc. Increases Stake in LifeMD, Inc. (NASDAQ:LFMD)

D. E. Shaw & Co. Inc. boosted its position in shares of LifeMD, Inc. (NASDAQ:LFMD) by 825.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 158,423 shares of the company’s stock after purchasing an additional 141,307 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.37% of LifeMD worth $784,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Bridgeway Capital Management LLC boosted its holdings in shares of LifeMD by 7.2% during the 4th quarter. Bridgeway Capital Management LLC now owns 269,157 shares of the company’s stock valued at $1,332,000 after acquiring an additional 18,000 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of LifeMD during the 4th quarter valued at about $52,000. Bank of America Corp DE boosted its holdings in shares of LifeMD by 48.3% during the 4th quarter. Bank of America Corp DE now owns 41,946 shares of the company’s stock valued at $208,000 after acquiring an additional 13,670 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of LifeMD during the 4th quarter valued at about $279,000. Finally, Northern Trust Corp boosted its holdings in shares of LifeMD by 2.1% during the 4th quarter. Northern Trust Corp now owns 323,974 shares of the company’s stock valued at $1,604,000 after acquiring an additional 6,634 shares during the last quarter. 35.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CMO Jessica Friedeman sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $5.66, for a total value of $169,800.00. Following the transaction, the chief marketing officer now owns 170,000 shares of the company’s stock, valued at approximately $962,200. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Justin Schreiber sold 21,995 shares of the firm’s stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $7.53, for a total transaction of $165,622.35. Following the sale, the chief executive officer now owns 2,553,726 shares in the company, valued at approximately $19,229,556.78. The trade was a 0.85% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 101,995 shares of company stock valued at $724,422. 15.97% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on LFMD shares. B. Riley raised shares of LifeMD to a “strong-buy” rating in a report on Tuesday, March 11th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of LifeMD in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price target on shares of LifeMD in a report on Tuesday, March 11th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, LifeMD presently has a consensus rating of “Buy” and an average price target of $11.00.

LifeMD Trading Up 0.3%

LFMD opened at $11.53 on Friday. The company has a market cap of $524.02 million, a price-to-earnings ratio of -18.02 and a beta of 2.22. The company’s 50 day moving average is $6.84 and its 200 day moving average is $6.09. LifeMD, Inc. has a 12-month low of $3.99 and a 12-month high of $11.65.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.05. The business had revenue of $65.70 million during the quarter, compared to analysts’ expectations of $62.47 million. As a group, analysts predict that LifeMD, Inc. will post -0.56 EPS for the current fiscal year.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.